MK0966; Rofecoxib / Duration of Treatment: 156 weeks + Placebo/ Duration of Treatment: 156 weeks
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Colorectal Adenoma
Conditions
Colorectal Adenoma
Trial Timeline
Dec 23, 1999 → Sep 1, 2004
NCT ID
NCT00282386About MK0966; Rofecoxib / Duration of Treatment: 156 weeks + Placebo/ Duration of Treatment: 156 weeks
MK0966; Rofecoxib / Duration of Treatment: 156 weeks + Placebo/ Duration of Treatment: 156 weeks is a phase 3 stage product being developed by Merck for Colorectal Adenoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00282386. Target conditions include Colorectal Adenoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00282386 | Phase 3 | Completed |
Competing Products
20 competing products in Colorectal Adenoma